Literature DB >> 1906385

Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.

Y Ikeda1, G Toda, N Hashimoto, N Umeda, K Miyake, M Yamanaka, K Kurokowa.   

Abstract

The occurrence of antibodies against recombinant human interferon-alpha 2a (IFN-alpha 2a) in patients with acute viral hepatitis (AVH) was examined by ELISA. Naturally occurring IgG anti-IFN-alpha 2a were found in 50% of patients with type A, 50% of those with type B and in 8.3% of those with non-A, non-B AVH. The corresponding frequencies of IgM antibodies were 80%, 30% and 33.3%, respectively. IgM anti-IFN-alpha 2a were found more frequently in patients with AVH type A than in normal control subjects (P less than 0.01). Anti-IFN-alpha 2a were detectable at the highest frequency 3 weeks after acute onset and then became negative. An absorption experiment revealed that IgM anti-IFN-alpha 2a did not cross-react with recombinant human IFN-alpha 2b. Immunoblotting analysis confirmed the binding of antibodies to IFN-alpha 2a. Sera positive for IgG and/or IgM anti-IFN-alpha 2a were unable to neutralize IFN-alpha 2a. The appearance of anti-IFN-alpha 2a was not correlated with disease severity. There was no evidence to suggest that anti-IFN-alpha 2a impaired the elimination of hepatitis virus. This is the first study to demonstrate the occurrence of anti-IFN-alpha 2a in patients with AVH. Detection of anti-IFN-alpha 2a may be useful for clarifying any underlying immune events in various diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906385      PMCID: PMC1535714          DOI: 10.1111/j.1365-2249.1991.tb05686.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.

Authors:  R G Steis; J W Smith; W J Urba; J W Clark; L M Itri; L M Evans; C Schoenberger; D L Longo
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Clinical significance of anti-IFN-alpha antibody titres during interferon therapy.

Authors:  P von Wussow; M Freund; B Block; H Diedrich; H Poliwoda; H Deicher
Journal:  Lancet       Date:  1987-09-12       Impact factor: 79.321

4.  Natural antibodies to IFN-gamma in man and their increase during viral infection.

Authors:  A Caruso; C Bonfanti; D Colombrita; M De Francesco; C De Rango; I Foresti; F Gargiulo; R Gonzales; G Gribaudo; S Landolfo
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

5.  Interferon system in acute viral hepatitis.

Authors:  S Levin; T Hahn
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

6.  Antibodies to human leucocyte interferons in cancer patients.

Authors:  P W Trown; M J Kramer; R A Dennin; E V Connell; A V Palleroni; J Quesada; J U Gutterman
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

7.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

8.  Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease.

Authors:  B Pozzetto; K E Mogensen; M G Tovey; I Gresser
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

9.  Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein.

Authors:  Y Ikeda; G Toda; N Hashimoto; S Aotsuka; R Yokohari; T Maruyama; H Oka
Journal:  Hepatology       Date:  1987 Mar-Apr       Impact factor: 17.425

10.  Detection of anti-interferon antibodies in systemic lupus erythematosus.

Authors:  B E Suit; D Axelrod; H M Moutsopoulos; J L Decker; J J Hooks
Journal:  Clin Exp Rheumatol       Date:  1983 Apr-Jun       Impact factor: 4.473

View more
  10 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

3.  Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.

Authors:  M B Hansen; M Svenson; K Bendtzen
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

Review 4.  Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity.

Authors:  Aristine Cheng; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2022-01       Impact factor: 14.290

5.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

Authors:  C Ross; M Svenson; M B Hansen; G L Vejlsgaard; K Bendtzen
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

8.  Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.

Authors:  A Meager; M Wadhwa; P Dilger; C Bird; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

9.  Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma.

Authors:  Beate Kampmann; Cheryl Hemingway; Alick Stephens; Robert Davidson; Anna Goodsall; Suzanne Anderson; Mark Nicol; Elisabeth Schölvinck; David Relman; Simon Waddell; Paul Langford; Brian Sheehan; Lynn Semple; Katalin A Wilkinson; Robert J Wilkinson; Stanley Ress; Martin Hibberd; Michael Levin
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

10.  Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.

Authors:  Shiyu Sun; Yueqi Cai; Tian-Zhang Song; Yang Pu; Lin Cheng; Hairong Xu; Jing Sun; Chaoyang Meng; Yifan Lin; Haibin Huang; Fang Zhao; Silin Zhang; Yu Gao; Jian-Bao Han; Xiao-Li Feng; Dan-Dan Yu; Yalan Zhu; Pu Gao; Haidong Tang; Jincun Zhao; Zheng Zhang; Jiaming Yang; Zhenxiang Hu; Yang-Xin Fu; Yong-Tang Zheng; Hua Peng
Journal:  Cell Res       Date:  2021-07-15       Impact factor: 25.617

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.